ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease

As efgartigimod gains traction in myasthenia gravis, argenx is out to prove its antibody fragment is no one hit wonder. Now, armed with a phase 3 win in primary immune thrombocytopenia (ITP), the company is bolstering its thesis that the neonatal-receptor-binding drug can drive down antibodies implicated across a host of autoimmune diseases.

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease